Rifalazil and derivative compounds show potent efficacy in a mouse model of H. pylori colonization

David M Rothstein; Steve Mullin; Klari Sirokman; Karen L Söndergaard; Starrla Johnson; Judith K Gwathmey; John van Duzer; Christopher K Murphy

doi:10.1038/ja.2008.64

Rifalazil and derivative compounds show potent efficacy in a mouse model of H. pylori colonization

J Antibiot (Tokyo). 2008 Aug;61(8):485-8. doi: 10.1038/ja.2008.64.

Authors

David M Rothstein¹, Steve Mullin, Klari Sirokman, Karen L Söndergaard, Starrla Johnson, Judith K Gwathmey, John van Duzer, Christopher K Murphy

Affiliation

¹ ActivBiotics, Inc, Lexington, MA 02421, USA. drothstein@rcn.com

PMID: 18997386
DOI: 10.1038/ja.2008.64

Abstract

The rifamycin rifalazil (RFZ), and derivatives (NCEs) were efficacious in a mouse model of Helicobacter pylori colonization. Select NCEs were more active in vitro and showed greater efficacy than RFZ. A systemic component contributes to efficacy.

MeSH terms

Animals
Antibiotics, Antitubercular / pharmacology*
Disease Models, Animal
Helicobacter Infections / drug therapy*
Helicobacter Infections / microbiology
Helicobacter pylori / drug effects
Helicobacter pylori / growth & development*
Mice
Mice, Inbred C57BL
Microbial Sensitivity Tests
Rifamycins / pharmacology*

Substances

Antibiotics, Antitubercular
Rifamycins
KRM 1648